One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
about
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseTiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseTiotropium for stable chronic obstructive pulmonary diseaseCASINO: surgical or nonsurgical treatment for cervical radiculopathy, a randomised controlled trialTiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions."Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD.Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary diseaseEvaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease.Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.Reliability and validity of a Dutch version of the Leicester Cough Questionnaire.Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study.Differences in COPD-related readmissions to primary and secondary care hospitals.Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis.Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease: the evidence for use of tiotropium.Optimizing economic outcomes in the management of COPD.Pharmacoeconomics in COPD: lessons for the futureA UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.Differentiating COPD from asthma in clinical practice.Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality.Role of tiotropium in the treatment of COPD.Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease.Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections.Chronic airflow limitation in developing countries: burden and priorities.Tiotropium bromide for chronic obstructive pulmonary disease.Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.The effect of tiotropium bromide on health-related quality of life in chronic obstructive pulmonary disease.Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations.A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
P2860
Q24187073-A9A67103-5311-443C-A08F-62978D7F5122Q24198068-958218CE-981A-48FA-B5E5-9610F6F8C3C9Q24200476-54F0AC4E-091D-447F-9DD5-58E8CA1D5D94Q24246991-A472E9E3-213D-4AC3-AA6D-CF463071D3F9Q33574494-C90D1C50-523D-4E8E-A047-0324E38DE051Q33693222-ADC05F5D-851B-45FE-A39F-83ABE74395B0Q33693227-8E7B9DE7-308F-4FF2-9239-622BF54B09FBQ33796149-03910F56-A4B3-4339-8E2B-125F40DF4AC3Q34554784-B2A08291-B97B-4FBE-8A39-B2E8E20C2B2DQ35205369-49FE69E8-B76D-4D54-8E8A-2B6B0CF0223EQ35537594-C382EBAB-0EE9-4868-A1B7-6C2925D05873Q35537629-977C57C4-62C6-43DC-B338-52182012B313Q35649145-E61EEED5-BBBD-4D7E-902B-6BF24208164FQ35696088-AA398210-0DA8-40E4-95DB-B9C1F76208E5Q35880368-095D4032-5E44-4608-AB17-6CCF8EDE9C63Q36135425-ABEEAF0A-9DB8-4CDA-91EA-46C13B2C368AQ36184259-9AABACA8-8FF9-4E6D-A1FB-4948E8DBD6EAQ36200675-79647A9B-A0AE-4C3D-893C-C7D4F9FFAF56Q36405313-DD5F724F-0B94-405D-8B29-378EAB8037DDQ36859405-63F755EF-CF1D-4D61-80AD-3AD9D6934942Q36859464-AEC4B2AC-6CF4-425E-BC6E-7CBC47D976C2Q36875110-2B42611C-B087-4DC7-9383-BD9D4794EBAFQ36951507-0B86E027-5C1F-4E66-A8A7-E31B7E30ED59Q37017238-7390C6CC-ADCE-47EB-B28E-BADDC06C010DQ37017516-99D9624E-27FB-43D5-9984-53D71B578389Q37177278-E7B20C29-656D-4892-998B-8AB27392B9F2Q37221196-169F934F-71DD-4CAA-A6E9-6FF0F88C38F9Q37224498-E871DF3D-4CF7-419E-9755-C47C46A1058EQ37225477-589E6997-77D5-4F88-A904-7DF1A2A457F0Q37755016-EA2A67F7-46AE-412B-8B38-D7D4367E9B0CQ37992679-3E19001F-D1ED-4704-A2AC-C21605A2A267Q38068886-FEDEAF6F-B0F9-42A0-98A3-453718FF5BDEQ43042782-C044851D-5628-4200-A81A-59EA7EEBF3D6Q45848789-5518AD12-12A0-4EC6-988C-E57AD0929DBAQ50016205-E834DB5B-EEAA-4266-819D-B5675C216FC5Q51103821-B6FFE570-633D-4943-8909-563C0DFEEBFD
P2860
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
One-year cost-effectiveness of ...... obstructive pulmonary disease.
@ast
One-year cost-effectiveness of ...... obstructive pulmonary disease.
@en
type
label
One-year cost-effectiveness of ...... obstructive pulmonary disease.
@ast
One-year cost-effectiveness of ...... obstructive pulmonary disease.
@en
prefLabel
One-year cost-effectiveness of ...... obstructive pulmonary disease.
@ast
One-year cost-effectiveness of ...... obstructive pulmonary disease.
@en
P2093
P1476
One-year cost-effectiveness of ...... obstructive pulmonary disease
@en
P2093
J A Van Noord
J B Oostenbrink
P304
P356
10.1183/09031936.03.00083703
P577
2004-02-01T00:00:00Z